16 research outputs found
Secukinumab in plaque psoriasis--results of two phase 3 trials.
No full textInterleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis
2.0 Å X-ray structure of the ternary complex of 7,8-dihydro-6-hydroxymethylpterinpyrophosphokinase from Escherichia coli
No full textThe Structural Mechanism for Half-the-Sites Reactivity in an Enzyme, Thymidylate Synthase, Involves a Relay of Changes between Subunits
No full textIdentification and Characterization of an Allosteric Inhibitory Site on Dihydropteroate Synthase
No full textInsights into the drug resistance induced by the BaDHPS mutations: molecular dynamic simulations and MM/GBSA studies
No full text
